Compare · ELV vs VCYT
ELV vs VCYT
Side-by-side comparison of Elevance Health Inc. (ELV) and Veracyte Inc. (VCYT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and VCYT operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.24B, about 23.2x VCYT ($3.89B).
- VCYT has been more active in the news (17 items in the past 4 weeks vs 3 for ELV).
- Both have 23 recent analyst ratings on file.
- Company
- Elevance Health Inc.
- Veracyte Inc.
- Price
- $419.74+0.98%
- $48.34-0.83%
- Market cap
- $90.24B
- $3.89B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 3
- 17
- Recent ratings
- 23
- 23
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Veracyte Inc.
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc.; and Bayer AG. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)
Latest VCYT
- Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.
- EVP, General Counsel Mcguire Annie sold $158,036 worth of shares (3,176 units at $49.76) as part of a pre-agreed trading plan and covered exercise/tax liability with 3,292 shares, decreasing direct ownership by 5% to 137,240 units (SEC Form 4) to satisfy withholding obligation
- VP, Chief Accounting Officer Wygant Jonathan covered exercise/tax liability with 1,361 shares, decreasing direct ownership by 3% to 44,073 units (SEC Form 4) to satisfy withholding obligation
- Chief Financial Officer Chambers Rebecca covered exercise/tax liability with 3,693 shares and sold $177,083 worth of shares (3,561 units at $49.73) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 173,280 units (SEC Form 4) (withholding obligation)
- Chief Scientific & Med Officer Febbo Phillip G. covered exercise/tax liability with 3,730 shares, decreasing direct ownership by 2% to 149,797 units (SEC Form 4) to cover taxes
- Chief Executive Officer Stapley Marc covered exercise/tax liability with 9,012 shares, exercised 138,051 shares at a strike of $36.60 and sold $6,919,585 worth of shares (138,051 units at $50.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 440,494 units (SEC Form 4) (tax withholding)
- Global Chief Commercial Off Leite John sold $699,732 worth of shares (13,975 units at $50.07) as part of a pre-agreed trading plan and covered exercise/tax liability with 4,059 shares, decreasing direct ownership by 12% to 132,305 units (SEC Form 4) (withholding obligation)
- Wolfe Research resumed coverage on Veracyte with a new price target
- Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
- ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer